Cyclophilin D deficiency attenuates mitochondrial perturbation and ameliorates hepatic steatosis

Xiaolei Wang1,2,3, Heng Du4, Shanshan Shao1,2,3

  • 1Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.

Insights

Cyclophilin D (CypD) excess opening of the mitochondrial permeability transition pore (mPTP) drives liver dysfunction and fatty liver disease. Inhibiting CypD protects against hepatic steatosis.

Area of Science:

  • Mitochondrial Biology
  • Hepatology
  • Molecular Medicine

Background:

  • The mitochondrial permeability transition pore (mPTP) is crucial for cell homeostasis.
  • The role of mPTP and cyclophilin D (CypD) in hepatic steatosis remains unclear.

Purpose of the Study:

  • To investigate the role of CypD in mediating hepatic mitochondrial dysfunction and steatosis.
  • To explore therapeutic strategies targeting CypD for fatty liver disease.

Main Methods:

  • Utilized high-fat diet-induced mouse models of hepatic steatosis.
  • Employed genetic knockout and pharmacological inhibition of CypD.
  • Investigated the involvement of p38 mitogen-activated protein kinase and Ire1α signaling pathways.

Main Results:

  • Increased CypD expression induced mitochondrial dysfunction preceding triglyceride accumulation.
  • Genetic or pharmacological CypD inhibition ameliorated mitochondrial dysfunction and reduced lipogenesis.
  • Overexpression of CypD aggravated hepatic steatosis.
  • Blocking p38 MAPK or Ire1α mitigated CypD-induced steatosis.

Conclusions:

  • Excessive mPTP opening, driven by CypD, causes mitochondrial dysfunction and hepatic steatosis.
  • Targeting CypD is a promising therapeutic approach for fatty liver disease.

Related Concept Videos

Transcription Attenuation in Prokaryotes02:42

Transcription Attenuation in Prokaryotes

Transcriptional attenuation occurs when RNA transcription is prematurely terminated due to the formation of a terminator mRNA hairpin structure.  Bacteria use these hairpins to regulate the transcription process and control the synthesis of several amino acids including histidine, lysine, threonine, and phenylalanine. Transcription attenuation takes place in the non-coding regions of mRNA.
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
18.6K
Animal Mitochondrial Genetics02:59

Animal Mitochondrial Genetics

Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
9.3K
Comparing Mitochondrial, Chloroplast, and Prokaryotic Genomes02:16

Comparing Mitochondrial, Chloroplast, and Prokaryotic Genomes

The present-day mitochondrial and chloroplast genomes have retained some of the characteristics of their ancestral prokaryotes and also have acquired new attributes during their evolution within eukaryotic cells. Like prokaryotic genomes, mitochondrial and chloroplast genomes neither bind with histone-like proteins nor show complex packaging into chromosome-like structures, as observed in eukaryotes. Unlike mitotic cell divisions observed in eukaryotic cells, mitochondria and chloroplasts...
17.1K
Export of Mitochondrial and Chloroplast Genes02:19

Export of Mitochondrial and Chloroplast Genes

A eukaryotic cell can have up to three different types of genetic systems: nuclear, mitochondrial, and chloroplast. During evolution, organelles have exported many genes to the nucleus; this transfer is still ongoing in some plant species. Approximately 18% of the Arabidopsis thaliana nuclear genome is thought to be derived from the chloroplast’s cyanobacterial ancestor, and around 75% of the yeast genome derived from the mitochondria’s bacterial ancestor. This export has occurred...
4.2K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
282
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.4K